跳至主要内容
临床试验/JPRN-UMIN000001265
JPRN-UMIN000001265已完成3 期

Pilot study of chemopreventive effect of pioglitazone for colorectal cancer using aberrant crypt foci as a biomarker - pioglitazone for colorectal cancer chemoprevention

Gastroenterology Division, Yokohama City University Graduate School of Medicine0 个研究点目标入组 40 人开始时间: 2008年7月24日最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
40

研究概览

简要总结

After administration of pioglitazone, the reduction in the number of ACF was observed.(The Joint Meeting of the 3rd ISC International Conference on Cancer Therapeutics and the 11th International Symposium on Cancer Chemotherapy, Tokyo, Japan, December 2006)

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • a. Liver cirrhosis or chronic hepatic, chronic renal failure b. Women who are pregnant or with a possibility of pregnancy c. Alcohol dependence or drug dependence d. Drug allergy e. Heart failure f. Those who have started to use different medication for diabetes mellitus from pioglitazone-alone (including insulin) in study period g. The patient that it is already taken pioglitazone h. History of cancer i. Family history of colorectal cancer j. The patient currently taking NSAIDs k. Inadequate to entry to this study

研究者

发起方
Gastroenterology Division, Yokohama City University Graduate School of Medicine

相似试验